mainstay therapy acute bronchospasm associated asthma chronic obstructive pulmonary disease beta2agonists used maintaining disease control respiratory disorders review describes compares pharmacology beta2agonists explains differences translate differences efficacy adverse effects questions commonly asked clinicians regarding efficacy safety beta2agonists include issues cardiovascular effects tolerance bronchodilator bronchoprotective effects blunting albuterol response beta2agonists potential masking worsening asthma control role beta2agonists adjunctive therapy inhaled corticosteroids maintaining asthma control pharmacogenetics play role determining patients risk reduced response continued use racemic albuterol contains mixture questioned data preclinical clinical studies suggesting causes proinflammatory effects increase bronchial hyperreactivity preclinical clinical effects stereoisomers reviewed data describing efficacy safety levalbuterol racemic albuterol presented short acting long acting beta2 agonists beta2 adrenergic mediated short long acting long acting long acting beta2 agonist r albuterol s albuterol s albuterol r albuterol